Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7) with high rate of signet cell component: Final results of the multicenter, randomized phase II/III trial of the German AIO and Italian GOIM.

TO Goetze; RD Hofheinz; H Schmalenberg; D Strumberg; E Goekkurt; S Angermeier; T Zander; J Potenberg; HG Kopp; D Pink; Gabriele Siegler; M Schenk; F De Vita; E Maiello; T Gaiser; D Sookthai; T Brulin; C Pauligk; N Homann; SE Al-Batran

Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7) with high rate of signet cell component: Final results of the multicenter, randomized phase II/III trial of the German AIO and Italian GOIM.

TO Goetze, RD Hofheinz, H Schmalenberg, D Strumberg, E Goekkurt, S Angermeier, T Zander, J Potenberg, HG Kopp, D Pink, Gabriele Siegler, M Schenk, F De Vita, E Maiello, T Gaiser, D Sookthai, T Brulin, C Pauligk, N Homann, SE Al-Batran

Universitätsklinik für Innere Medizin 5 - Onkologie und Hämatologie

Publikation: Beitrag in Fachzeitschrift › Abstrakt (Zeitschrift) › Begutachtung

2 Quellenangaben (Web of Science)

Originalsprache	Englisch
Fachzeitschrift	JOURNAL OF CLINICAL ONCOLOGY
Jahrgang	40
Ausgabenummer	16
Publikationsstatus	Veröffentlicht - 2022

Dieses zitieren

Goetze, TO., Hofheinz, RD., Schmalenberg, H., Strumberg, D., Goekkurt, E., Angermeier, S., Zander, T., Potenberg, J., Kopp, HG., Pink, D., Siegler, G., Schenk, M., De Vita, F., Maiello, E., Gaiser, T., Sookthai, D., Brulin, T., Pauligk, C., Homann, N., & Al-Batran, SE. (2022). Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7) with high rate of signet cell component: Final results of the multicenter, randomized phase II/III trial of the German AIO and Italian GOIM. JOURNAL OF CLINICAL ONCOLOGY , 40(16).

Goetze, TO ; Hofheinz, RD ; Schmalenberg, H et al. / Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7) with high rate of signet cell component: Final results of the multicenter, randomized phase II/III trial of the German AIO and Italian GOIM. in: JOURNAL OF CLINICAL ONCOLOGY 2022 ; Jahrgang 40, Nr. 16.

@article{9179ad99b83a4e3f94cd8ef72792f897,

title = "Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7) with high rate of signet cell component: Final results of the multicenter, randomized phase II/III trial of the German AIO and Italian GOIM.",

author = "TO Goetze and RD Hofheinz and H Schmalenberg and D Strumberg and E Goekkurt and S Angermeier and T Zander and J Potenberg and HG Kopp and D Pink and Gabriele Siegler and M Schenk and {De Vita}, F and E Maiello and T Gaiser and D Sookthai and T Brulin and C Pauligk and N Homann and SE Al-Batran",

year = "2022",

language = "English",

volume = "40",

journal = "JOURNAL OF CLINICAL ONCOLOGY ",

issn = "0732-183X",

publisher = "Lippincott Williams & Wilkins ",

number = "16",

}

Goetze, TO, Hofheinz, RD, Schmalenberg, H, Strumberg, D, Goekkurt, E, Angermeier, S, Zander, T, Potenberg, J, Kopp, HG, Pink, D, Siegler, G, Schenk, M, De Vita, F, Maiello, E, Gaiser, T, Sookthai, D, Brulin, T, Pauligk, C, Homann, N & Al-Batran, SE 2022, 'Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7) with high rate of signet cell component: Final results of the multicenter, randomized phase II/III trial of the German AIO and Italian GOIM.', JOURNAL OF CLINICAL ONCOLOGY , Jg. 40, Nr. 16.

Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7) with high rate of signet cell component: Final results of the multicenter, randomized phase II/III trial of the German AIO and Italian GOIM. / Goetze, TO; Hofheinz, RD; Schmalenberg, H et al.
in: JOURNAL OF CLINICAL ONCOLOGY , Jahrgang 40, Nr. 16, 2022.

Publikation: Beitrag in Fachzeitschrift › Abstrakt (Zeitschrift) › Begutachtung

TY - JOUR

T1 - Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7) with high rate of signet cell component: Final results of the multicenter, randomized phase II/III trial of the German AIO and Italian GOIM.

AU - Goetze, TO

AU - Hofheinz, RD

AU - Schmalenberg, H

AU - Strumberg, D

AU - Goekkurt, E

AU - Angermeier, S

AU - Zander, T

AU - Potenberg, J

AU - Kopp, HG

AU - Pink, D

AU - Siegler, Gabriele

AU - Schenk, M

AU - De Vita, F

AU - Maiello, E

AU - Gaiser, T

AU - Sookthai, D

AU - Brulin, T

AU - Pauligk, C

AU - Homann, N

AU - Al-Batran, SE

PY - 2022

Y1 - 2022

M3 - Abstract (Journal)

SN - 0732-183X

VL - 40

JO - JOURNAL OF CLINICAL ONCOLOGY

JF - JOURNAL OF CLINICAL ONCOLOGY

IS - 16

ER -

Goetze TO, Hofheinz RD, Schmalenberg H, Strumberg D, Goekkurt E, Angermeier S et al. Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7) with high rate of signet cell component: Final results of the multicenter, randomized phase II/III trial of the German AIO and Italian GOIM. JOURNAL OF CLINICAL ONCOLOGY . 2022;40(16).